GlassScriptPhysician profile
Sanjay Aggarwal
NPI 1912927658
$53,564.62
in general payments reported to CMS, 2019-2025
47 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $39K · 2021: $6,230 · 2022: $1,784 · 2023: $1,757 · 2024: $1,800 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,247.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kadmon Corporation LLC | $39,900.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,968.65 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,900.98 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,713.44 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,172.60 | 2020-2025 | Jardiance, Combivent Respimat, Spiriva Respimat |
| Lilly USA, LLC | $713.53 | 2019-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $615.55 | 2019-2025 | |
| Indivior INC. | $614.69 | 2019-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $572.50 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Novo Nordisk INC | $515.65 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $378.00 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $373.75 | 2021-2023 | |
| Gilead Sciences, INC. | $291.23 | 2019-2023 | |
| Allergan, INC. | $233.66 | 2020 | |
| Orexo US, INC. | $225.11 | 2019-2025 | Zubsolv |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.